ArriVent BioPharma, Inc. Common Stock

AVBPNASDAQ • USD
11.86 USD
↘ 1.15 (8.84%)🟢LIVE (AS OF 02:00 PM EST)
🟢Market: OPEN

AVBP is currently priced at $11.86. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. AVBP is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Nov 13, 2026.

Open?$12.86
High?$13.85
Low?$11.86
Prev. Close?$13.01
Volume?179.3K
Avg. Volume?2.1M
VWAP?$12.43
Rel. Volume?0.08x
Bid / Ask
Bid?$10.48 × 200
Ask?$12.02 × 100
Spread?$1.54
Midpoint?$11.25
Valuation & Ratios
Market Cap?672.9M
Shares Out?51.7M
Float?33.5M
Float %?68.0%
P/E Ratio?N/A
P/B Ratio?1.71
EPS?-$3.27
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Employees
77
Market Cap
672.9M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2024-01-26
Address
18 CAMPUS BLVD.
NEWTOWN SQUARE, PA 19073-3269
Phone: 240-780-6356
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
56
Piotroski F-Score?0/9Weak
Altman Z-Score?15.00Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?17.29%High
Short Interest?5.8M
Days to Cover?3.4
Free Float33.5M
Avg Daily Volume1.7M
Settlement Date2026-10-30
Financial Health
Current Ratio?17.64Strong
Quick Ratio?17.64Strong
Cash Ratio?4.81Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
82
1.71CHEAP▾
P/S?
Peers
100
S&P
3
134.58HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.0CHEAP▾
EV/Sales?
Peers
100
S&P
3
111.87HIGH▾
Returns & Efficiency
ROE?
S&P
3
-43.0%WEAK▾
ROA?
S&P
3
-40.5%WEAK▾
Cash Flow & Enterprise
FCF?$-149058000
Enterprise Value?$559.3M
Fundamentals ratios updated end of day